EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Use of Biologics to Treat Asthma during Pregnancy and Adverse Events in Pregnant Women and Newborns: A Global Pharmacovigilance Analysis

Einsatz von Biologika zur Behandlung von Asthma während der Schwangerschaft und unerwünschte Ereignisse bei Schwangeren und Neugeborenen: globale Pharmakovigilanzanalyse

Wonwoo Jang, Hyesu Jo, Jaeyu Park, Seokjun Kim, Hanseul Cho, Yi Deun Jeong, Yejun Son, Damiano Pizzol, Nikolaos G Papadopoulos, Dong Keon Yon, Dong Keon Yon

International Archives of Allergy and Immunology · 17.01.2025 · 186 (9) · 875-888

DOI: 10.1159/000543490 ↗

Auf einen Blick

In VigiBase ausgewertete Schwangerschaftsberichte zu Asthma-Medikamenten zeigten je nach Wirkstoff unterschiedliche Meldungsfrequenzen für fetale und geburtsbezogene Ereignisse. Für mehrere Biologika wurden höhere Meldungsfrequenzen spontaner fötaler Todesfälle berichtet.

Fragestellung

Wie sind Schwangerschafts-, Fetal- und Neugeborenenereignisse bei der Exposition gegenüber Biologika zur Asthmatherapie im Vergleich zu anderen nicht-biologischen Asthmamedikamenten gemeldet?

Methode

Globale Case-Non-Case-Analyse von VigiBase-Berichten zwischen 1980 und 2023 zu Schwangerschafts- oder Fetusreaktionen unter Asthmamedikamenten; Vergleich von Biologika mit anderen nicht-biologischen Asthmamedikamenten.

Ergebnisse

15.715 schwangerschaftsbezogene Berichte. Reslizumab: niedrigere Meldungsfrequenz unerwünschter Ereignisse (ROR 0,19; 95 %-KI 0,05–0,67). Omalizumab, Mepolizumab und Dupilumab zeigten häufiger spontane fötale Todesfälle; Benralizumab zeigte niedrigere Frequenzen spontaner Aborte, aber höhere geburtsbezogene Komplikationen.

Einschränkungen

Pharmakovigilanzdaten aus Meldesystemen; der Abstract nennt den Bedarf an weiterer gut geplanter Forschung und strengerem Monitoring.

Schlussfolgerung der Autor:innen

Die Studie unterstreicht den Bedarf an weiterer gut geplanter Forschung zu diesen übergemeldeten Ereignissen und an strengerem Monitoring.

Kernaussagen

  • 15.715 schwangerschaftsbezogene Berichte wurden analysiert.
  • Je nach Biologikum unterschiedliche RORs für fötale und geburtsbezogene Ereignisse.
  • Die Autor:innen fordern weitere Forschung und engmaschigeres Monitoring.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 17.01.2025. Verfasst von Wonwoo Jang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, …. Hauptthemen laut MEDLINE: Asthma, Biological Products, Pregnancy Complications, Anti-Asthmatic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite the increasing evidence supporting the use of biologics for treating severe asthma, there is a lack of evidence regarding their use in pregnant women. This study aims to evaluate the safety of biologics for pregnant women, utilizing global pharmacovigilance database.

Methods

Reports documented between 1980 and 2023 were extracted from the VigiBase that mentioned pregnancy- or fetus-related reactions with drugs indicated for asthma, including reslizumab, omalizumab, mepolizumab, dupilumab, benralizumab, and other non-biologics. A disproportionality analysis of case-non-case was conducted by calculating the reporting odds ratio (ROR) with 95% confidence interval (95% CI) of adverse maternal, fetal, and newborn outcomes associated with exposure to biologics compared with outcomes associated with other non-biologic asthma medications.

Results

A total of 15,715 pregnancy-related reports were analyzed. Reslizumab showed an overall lower reporting frequency of adverse events (ROR, 0.19; 95% CI, 0.05–0.67). Omalizumab (ROR, 3.88; 95% CI, 3.16–4.77), mepolizumab (ROR, 1.87; 95% CI, 1.05–3.36), and dupilumab (ROR, 5.34; 95% CI, 3.90–7.32) commonly showed higher frequencies of spontaneous fetal death. However, these three drugs also had lower frequencies of pregnancy and delivery complications, including preterm birth (omalizumab: ROR, 0.22; 95% CI, 0.16–0.31; mepolizumab: ROR, 0.10; 95% CI, 0.03–0.34; dupilumab: ROR, 0.07; 95% CI, 0.03–0.17), which are outcomes related to late pregnancy. In contrast, benralizumab (ROR, 0.69; 95% CI, 0.48–0.99) differed from the other biologics by showing lower frequencies of spontaneous fetal death (ROR, 0.69; 95% CI, 0.48–0.99) and spontaneous abortion (ROR, 0.47; 95% CI, 0.29–0.78) but higher frequencies of delivery complications (ROR, 1.32; 95% CI, 1.02–1.72), including preterm birth (ROR, 1.46; 95% CI, 1.14–1.86).

Conclusions

This global case-non-case study underscores the critical need for further well-designed research to investigate these overreported outcomes and emphasizes the importance of more rigorous monitoring efforts for these adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsPregnancy ComplicationsAnti-Asthmatic AgentsHumansFemalePregnancyPharmacovigilanceInfant, NewbornAdult

Stichwörter der Autor:innen

AsthmaBiologicsMonoclonal antibodyPregnancy

Substanzen

Biological ProductsAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
  • Department of Medicine, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
  • Department of Regulatory Science, Kyung Hee University, Seoul, Republic of Korea.
  • Health Unit Eni, Maputo, Mozambique.
  • Health Unit Eni, San Donato Milanese, Italy.
  • Allergy Department, Second Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.

Zitieren

APA

Jang, W., Jo, H., Park, J., Kim, S., Cho, H., Jeong, Y. D., Son, Y., Pizzol, D., Papadopoulos, N. G., Yon, D. K., & Yon, D. K. (2025). Use of Biologics to Treat Asthma during Pregnancy and Adverse Events in Pregnant Women and Newborns: A Global Pharmacovigilance Analysis. International Archives of Allergy and Immunology, 186(9), 875-888. https://doi.org/10.1159/000543490

Vancouver

Jang W, Jo H, Park J, Kim S, Cho H, Jeong YD, et al. Use of Biologics to Treat Asthma during Pregnancy and Adverse Events in Pregnant Women and Newborns: A Global Pharmacovigilance Analysis. International Archives of Allergy and Immunology. 2025;186(9):875-888. doi:10.1159/000543490

BibTeX
@article{Jang2025,
  author = {Jang, Wonwoo and Jo, Hyesu and Park, Jaeyu and Kim, Seokjun and Cho, Hanseul and Jeong, Yi Deun and Son, Yejun and Pizzol, Damiano and Papadopoulos, Nikolaos G and Yon, Dong Keon and Yon, Dong Keon},
  title = {Use of Biologics to Treat Asthma during Pregnancy and Adverse Events in Pregnant Women and Newborns: A Global Pharmacovigilance Analysis},
  journal = {International Archives of Allergy and Immunology},
  year = {2025},
  volume = {186},
  number = {9},
  pages = {875--888},
  doi = {10.1159/000543490}
}
Kostenlos starten →